SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both |
|
|
| Active, not recruiting | 3 | 99 | Europe, US, RoW | Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo | Eli Lilly and Company, Eli Lilly and Company | Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease | 07/24 | 02/25 | | |
